NCT03152019View on ClinicalTrials.gov

Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 22, 2017

Primary Completion Date

November 8, 2018

Study Completion Date

November 8, 2018

Conditions

Hemorrhagic Hereditary Telangiectasia (HHT)

Interventions

DRUG

Protopic® (Tacrolimus) 0.1% ointment

About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.

DRUG

Placebo

About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.

Trial Locations (3)

Unknown

Hôpital Femme Mère Enfant, Bron

CHU Estaing, Clermont-Ferrand

CHU de Montpellier, Montpellier

All Listed Sponsors

lead

Hospices Civils de Lyon

OTHER

NCT03152019 - Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT) | Biotech Hunter | Biotech Hunter